Undifferentiated nasopharyngeal carcinoma (NPC) is a cancer with high metastatic potential that is consistently associated with Epstein-Barr virus (EBV) infection. In this study, we have investigated the functional contribution of sphingosine-1-phosphate (S1P) signalling to the pathogenesis of NPC. We show that EBV infection or ectopic expression of the EBV-encoded latent genes (EBNA1, LMP1, and LMP2A) can up-regulate sphingosine kinase 1 (SPHK1), the key enzyme that produces S1P, in NPC cell lines. Exogenous addition of S1P promotes the migration of NPC cells through the activation of AKT; shRNA knockdown of SPHK1 resulted in a reduction in the levels of activated AKT and inhibition of cell migration. We also show that S1P receptor 3 (S1PR3) mRNA is overexpressed in EBV-positive NPC patient-derived xenografts and a subset of primary NPC tissues, and that knockdown of S1PR3 suppressed the activation of AKT and the S1P-induced migration of NPC cells. Taken together, our data point to a central role for EBV in mediating the oncogenic effects of S1P in NPC and identify S1P signalling as a potential therapeutic target in this disease.
Introduction
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is exceptionally prevalent in southern China and South East Asia [1, 2] . Approximately 75% of NPC patients present with late-stage disease and approximately 30% of these patients develop distant metastases post-therapy [1, 3] . Existing treatment for advanced disease is limited to concurrent chemoradiotherapy and unfortunately, due to the location of tumours in close proximity to vital organs in the head and neck region, most survivors of NPC have an impaired health-related quality of life [4, 5] . A deeper understanding of the molecular basis of NPC is required to inform innovations in the therapeutic approach.
Undifferentiated NPC is invariably associated with Epstein-Barr virus (EBV) infection [6] . EBV latent gene expression in NPC is restricted to Epstein-Barr Aberrant activation of S1P signalling in nasopharyngeal carcinoma 63 to generate S1P [9] . High expression of SPHK1 was shown to be associated with poor prognosis in NPC [10] , but the downstream biological consequences of elevated SPHK1 in NPC cells have not been studied. The pro-oncogenic effects of S1P have been suggested to be mainly a consequence of alterations in the expression or function of one or more of five known G protein-coupled receptors (GPCRs), S1PR1-5 [11] . We were particularly interested to explore if the aberrant activation of the SPHK1/S1P/S1PR axis could contribute to the migratory potential of NPC. We show for the first time that EBV infection enhances the expression of SPHK1 in NPC cells and that S1P induces migration of NPC cells by activating AKT through S1PR3.
Materials and methods

Cell lines, xenografts, and tissue samples
The cell lines used in this study included an immortalized nasopharyngeal epithelial cell line, NP69, and eight NPC-derived cell lines, of which seven were EBV-negative (CNE1, CNE2, HK1, HONE1, SUNE1, TW01, and TW04) and one was EBV-positive (C666-1). NPC cells stably infected with a recombinant EBV (Akata strain) or expressing individual EBV-encoded latent genes were generated as previously described [12] . Four NPC patient-derived EBV-positive xenografts (xeno-2117, xeno-666, C15, and C17) were used in this study [13] [14] [15] . Paraffin-embedded archival NPC and non-malignant nasopharyngeal tissue samples were obtained from the tissue bank of the Department of Anatomical and Cellular Pathology at the Prince of Wales Hospital, The Chinese University of Hong Kong (CUHK). The study protocol was approved by the Clinical Research Ethics Committee of the CUHK. All NPC samples were non-keratinizing EBER-positive. The study protocol was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee, Hong Kong. The clinical characteristics of the NPC samples can be found in the supplementary material, Table S1 .
Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Crawley, UK) and subjected to reverse transcription using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative PCR was performed in triplicate using an ABI Prism 7000 Sequence Detection System and TaqMan Gene Expression Assays (SPHK1: Hs00184211_m1; S1PR3: Hs00245464_s1; Applied Biosystems). GAPDH was amplified in the same reaction to serve as an internal control for normalization. Fold changes in gene expression were measured using the comparative threshold cycle method (ΔΔCt).
Western blotting
Cells were lysed in ice-cold NP40 lysis buffer [150 mM NaCl, 1% IGEPAL ® CA-630, 50 mM Tris-HCl (pH 8.0)] containing protease inhibitors (cocktail set III; Calbiochem, Merck Millipore, Darmstadt, Germany) and phosphatase inhibitors (Halt phosphatase inhibitor cocktail; Thermo Scientific, Rockford, IL, USA). Samples containing equal amounts of protein were separated under reducing conditions using SDS-PAGE and the proteins transferred to polyvinylidene difluoride membranes (Millipore, Watford, UK). The primary antibodies used in this study were anti-phospho-SPHK1 (Ser-225; SP1641; dilution 1:1000; ECM Biosciences, Versailles, KY, USA), anti-total SPHK1 (3297; dilution 1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-AKT (Ser473; 9271; dilution 1:1000; Cell Signaling Technology), anti-total AKT (9272; dilution 1:1000; Cell Signaling Technology), anti-α-tubulin (T9026; dilution 1:10000; Sigma-Aldrich, St Louis, MO, USA), and anti-β-actin (A5441; dilution 1:5000; Sigma-Aldrich). Bound antibodies were detected with peroxidase-conjugated secondary antibodies and Enhanced Chemiluminescence reagents (Advansta, Menlo Park, CA, USA).
Transwell migration and invasion assays
Migration assays were carried out using fibronectin-coated (10 μg/ml) polycarbonate filters (8 μm pore size, Transwell, Corning, Cambridge, MA, USA). Cells were incubated in RPMI-0.5% FBS overnight and resuspended in migration buffer [RPMI containing 0.25 mg/ml fatty acid-free human albumin (Sigma)]. 1 × 10 6 cells were plated into the upper chamber and allowed to migrate for 19 h in the presence or absence of S1P (Enzo Life Sciences, Farmingdale, NY, USA) in the lower chamber. Migrated cells were stained with 0.1% crystal violet and counted in five random fields. For experiments using inhibitors of AKT (LY294002; 1 μM; Merck, Darmstadt, Germany) and S1PR1/S1PR3 (VPC23019; 1 μM; Tocris Bioscience, Minneapolis, MN, USA), the inhibitors were added to the both the lower and the upper chambers and S1P (5 μM) was added to the lower chamber. For invasion assays, pre-coated invasion chambers (8 μm pore size, BD BioCoat Matrigel) were used and cells were allowed to invade for 48 h.
Knockdown of SPHK1, AKT, and S1PR3
Two SPHK1 shRNA lentiviral plasmids (pLKO.1/ shSPHK1_S1 and pLKO.1/shSPHK1_S2) and the non-targeting (control) shRNA (pLKO.1/NS) were kindly provided by Professor Chee-Onn Leong (International Medical University, Malaysia). Briefly, 293T cells were transfected with the lentiviral construct64 HM Lee et al 0.45 μm syringe filter. The viral supernatants and polybrene (8 μg/ml) were then added to plates cultured with NPC cells and incubated for 16 h. The virus-containing media were then removed and the cells were cultured in RPMI-10% FBS for an additional 48 h before selecting the transfected cells with 0.5-1 μg/ml puromycin. To knockdown AKT and S1PR3, pre-designed RNAi SMART pool reagents (AKT1: L-003000-00; S1PR3: LU-005208-00) were obtained from Dharmacon (Chicago, IL, USA) and used at 25 nM. 5 × 10 4 cells per well were seeded into six-well plates, cultured for 16 h, and then transfected with the relevant siRNA using oligofectamine (Invitrogen, Paisley, UK).
Expression of constitutively active AKT
The vector carrying a myristoylated form of AKT, 1036 pcDNA3 Myr HA Akt1 (Addgene plasmid # 9008) [16] , was used to express constitutively active AKT. Cells at 50% confluency were transfected with the 1036 pcDNA3 Myr HA Akt1 or the empty vector at a 3:1 FuGENE HD transfection reagent (Promega, Madison, WI, USA):DNA ratio. Cells were used in Transwell migration assays 24 h post-transfection.
RNA in situ hybridization S1PR3 mRNA expression in the NPC specimens was detected by an RNAscope 2.0 assay with a S1PR3-specific probe (Advanced Cell Diagnostics, Hayward, CA, USA). FFPE tissue and cell block sections (5 μm) were deparaffinized in xylene and then dehydrated in a series of ethanol in water. The S1PR3-specific probes were hybridized to the sections, followed by incubation with preamplifier, amplifier, and labelled probes.
The chromogenic detection procedures were performed according to the manufacturer's instructions. S1PR3 expression was assessed by assigning a proportion score and an intensity score. The proportion score relates to the percentage of tumour cells with brown signals (0-100). The intensity score represents the average abundance of signals in the tumour cells (0, none; 1, weak; 2, intermediate; 3, strong). The S1PR3 expression score was the product of the proportion and intensity scores, ranging from 0 to 300.
Analysis of microarray data
Microarray raw data, GSE12452 and GSE34573, were downloaded from GEO and re-analysed to identify genes differentially expressed between micro-dissected NPC tissues and normal nasopharyngeal epithelium. Probe level quantile normalization [17] , RMA (robust multi-array analysis) [18] , and MAS5 detection analyses were performed using the Affy package of the Bioconductor project (http://www.bioconductor.org). P values and fold changes were calculated using limma [19] . Affymetrix 'HG-Focus.na35.annot.csv' was used for probe set annotation. Probe sets with 'Negative Strand Matching Probes' were removed. Differentially expressed genes were identified using the criteria fold change > 1.5 and P value < 0.05.
Statistical analyses
All statistical analyses were performed using SPSS 23.0 for Windows (IBM Inc, Foster City, CA, USA) or GraphPad Prism Version 5 (GraphPad Software Inc, San Diego, CA, USA). For RT-qPCR and migration/invasion assays, statistical differences between experimental groups were evaluated by Student's t-test or one-way analysis of variance (ANOVA)/Dunnett's test. A receiver operating characteristic (ROC) curve was constructed using S1PR3 expression scores to select the best cut-off point (maximum sensitivity and specificity) that is relevant to patient survival [20] . NPC cases were grouped into cases with low (score 0-45) or high (score 46-200) expression of S1PR3. Kaplan-Meier survival analysis was used to correlate survival rates with S1PR3 expression and the survival probability differences were compared by log-rank test. Values of p < 0.05 were regarded as significant.
Results
EBV infection of NPC cells increases the expression of SPHK1
Given that SPHK1, the key enzyme that produces S1P, has been shown to be commonly expressed in primary NPC tissues [10] , we opted to investigate whether EBV infection could modulate SPHK1 levels in NPC cells. We first compared SPHK1 mRNA expression in eight NPC cell lines with that in the immortalized nasopharyngeal epithelial cell line NP69. Among the three NPC cell lines that expressed significantly higher levels of SPHK1, we had noted that C666-1, the only EBV-positive NPC cell line, showed exceptionally high expression of SPHK1 ( Figure 1A ). We subsequently found that SPHK1 mRNA abundance was significantly higher in six out of seven NPC cell lines stably infected with a recombinant EBV (Akata strain) (p < 0.01; Figure 1B ). After first validating the specificity of antibodies against total and phosphorylated SPHK1 proteins (supplementary material, Figure S1 ), we showed that while the increased expression of the total SPHK1 protein was confirmed in three representative EBV-infected NPC cell lines, the levels of phosphorylated SPHK1 protein were also increased in these cell lines ( Figure 1C ). Next, we investigated which EBV gene(s) were responsible for this effect. To do this, we examined SPHK1 expression in HONE1 cells individually transfected with EBNA1, LMP1 or LMP2A, all of which are expressed in NPC in vivo. We found that both the mRNA and the protein levels of SPHK1 were up-regulated by all three EBV latent genes in HONE1 cells, with the most marked effect in LMP2A-expressing cells ( Figure 1D ). We conclude that EBV infection can up-regulate the expression of SPHK1; hence high levels of S1P are likely to be present in EBV-positive NPC cells.
S1P enhances the migration of NPC cells
Next, we used Transwell assays to investigate the effects of S1P on the migration of NPC cells using three representative NPC cell lines (TW04, HONE1, and SUNE1). We found that the exogenous addition of S1P significantly increased the migration of all three cell lines (p < 0.001; Figure 2A ). Given that C666-1 cells do not migrate in Transwell assays, even in the presence of 10% FBS or S1P, we performed wound healing assays using charcoal-stripped FBS. Similarly, S1P enhanced C666-1 cell migration (supplementary material, Figure S2 ). S1P also promoted the invasion of SUNE1 cells (supplementary material, Figure S3 ). We next measured migration in HONE1 cells following their transduction with two different shRNAs targeting SPHK1 (shSPHK1_S1 or shSPHK1_S2), or with a non-targeting shRNA (NS), as a control. Reduced expression of both SPHK1 mRNA and protein in transfected HONE1 was confirmed by RT-qPCR and western blot analyses, respectively ( Figure 2B ). In line with the data that S1P induced NPC cell migration, knockdown of SPHK1 expression suppressed the migration of HONE1 cells (p < 0.001; Figure 2C ).
S1P induces NPC cell migration through activation of AKT
We next investigated the mechanism of S1P-induced migration of NPC cells. We focused on the AKT pathway firstly because AKT has been shown to be a central player in mediating the oncogenic effects of S1P and its activation promotes cancer cell migration in various solid tumour types [7] . Secondly, activation of the PI3K/AKT pathway is a common feature of NPC and this pathway is stimulated by the EBV-encoded LMP1 AKT by S1P was responsible for the increased migration, we treated NPC cells with a PI3K/AKT inhibitor, LY294002. After first confirming the inhibitory effects of LY294002 on AKT phosphorylation (supplementary material, Figure S4 ), we showed that treatment of HONE1 and SUNE1 with LY294002 led to a significant reduction in cell migration in the presence of S1P (p < 0.001; Figure 3B ). Similarly, knockdown of AKT with a pool of four siRNAs targeting AKT significantly suppressed the migration of both HONE1 and SUNE1 cell lines (p < 0.001; Figure 3C ). In keeping with these observations, the knockdown of SPHK1 also resulted in a significant reduction in the levels of activated AKT in HONE1 cells ( Figure 3D) . Furthermore, the expression of a constitutively active AKT was able to rescue the repressive effects of SPHK1 knockdown on cell migration (p < 0.001; Figure 3E ). Taken together, our results show that S1P induces the migration of NPC cells through the activation of AKT.
Overexpression of S1PR3 in NPC
We next explored which S1P receptors might be responsible for mediating the S1P-induced migration of NPC cells. Re-analyses of two published microarray datasets, GSE12452 [22] and GSE34573 [23] , revealed significant and consistent up-regulation of S1PR3 mRNA expression in micro-dissected NPC cells compared with normal epithelium (p < 0.05; Figure 4A ). Expression of the other four S1P receptor genes was either not significantly different or not consistently altered in both datasets (supplementary material, Table S2 ). We attempted to examine the expression and cellular localization of S1PR3 protein in primary NPC tissues using immunohistochemistry; however, none of the three anti-S1PR3 antibodies tested was suitable. Therefore, we opted to use sensitive RNA in situ hybridization (RNAscope) to examine the expression of S1PR3 in C666-1 cells; four EBV-positive NPC patient-derived xenografts (xeno-666, xeno-2117, C15, and C17); an independent cohort of 21 formalin-fixed, paraffin-embedded primary NPCs; and nine non-malignant nasopharyngeal samples. We showed that C666-1 cells, xeno-666, and C15 demonstrated strong staining for S1PR3, while weak expression was observed in xeno-2117 and C17 ( Figure 4B ). In tissue samples, normal surface epithelium and epithelium adjacent to the carcinoma were consistently negative, whereas S1PR3 expression was detected in 13 of 21 (62%) of the primary NPCs examined ( Figure 4C ). S1P mediates migration of NPC cell by activating AKT through S1PR3 the presence of S1P (p < 0.001; Figure 5A ). Next, we transfected SUNE1 cells with a pool of four siRNAs targeting S1PR3 and the reduced expression of S1PR3 was confirmed by RT-qPCR analysis ( Figure 5B ). We observed that knockdown of S1PR3 reduced the levels of activated AKT ( Figure 5C ) and partially suppressed the migration of SUNE1 cells in the presence of S1P (p < 0.001; Figure 5D ). To further confirm these effects, we co-transfected SUNE1 cells with a constitutively active AKT and S1PR3 siRNAs. Expression of a constitutively active AKT restored the migration of these cells (p < 0.001; Figure 5E ). We conclude that S1P enhances the migration of NPC cells via the activation of AKT by S1PR3. 
Discussion
S1P signalling affects many processes involved in carcinogenesis and there is now a growing appreciation that the oncogenic effects of S1P are dependent on the enzymes that generate or degrade S1P, and/or alterations in the expression of S1P receptors [7, 11] . Thus, the SPHK/S1P/S1PRs axis has become an attractive therapeutic target in cancer. Two functional SPHK isoforms, SPHK1 and SPHK2, have been identified in humans [24] . Whilst the role of SPHK2 in carcinogenesis remains to be fully explored, the tumour-promoting role of SPHK1 is well acknowledged [25] . Indeed, overexpression of SPHK1 has been reported in various types of cancer, including NPC [10, 25] . A wide variety of stimuli, including growth factors, GPCR agonists, cytokines, phorbol esters, and vitamin D3, can increase SPHK1 levels [26] . In the present study, we have identified a novel role for EBV in stimulating the expression and activation of SPHK1 in NPC cell lines. Although the mechanisms by which the EBV-encoded genes up-regulate the transcription of SPHK1 have yet to be determined, LMP1 and LMP2A are known to activate the ERK-MAPK pathway in NPC [27] and this, in turn, would likely result in the phosphorylation of SPHK1.
High-level expression of SPHK1 increases the production of S1P and elevated levels of S1P promote a number of malignant phenotypes associated with cancer cells, including proliferation, migration, invasion, and angiogenesis [7] . Focusing on the migratory phenotype, our data show convincingly that S1P promotes the migration of NPC cells through the activation of AKT and these effects were reversed by the knockdown of SPHK1. We further show that S1P activates AKT70 HM Lee et al of cancer cells is dependent on the expression pattern of S1P receptors [28] . S1PR1 and S1PR3 have been shown to stimulate cell migration by coupling to G i to activate Rac through PI3K; although S1PR2 is generally thought to inhibit cell migration via G 12/13 , we recently showed that S1PR2 contributes to the S1P-induced migration of oral cancer cells [29] . The involvement of S1PR3-mediated AKT activation in S1P-induced migration has previously been inferred indirectly in a limited number of studies. For example, S1P activated AKT in endothelial cells, ovarian cancer cells, and thyroid cancer cells, and treatment of these cells with LY294002 or wortmannin suppressed S1P-induced migration in a G i -dependent manner [30] [31] [32] . Although these studies used the S1PR1/3 inhibitor VPC23019 to reveal the possible involvement of S1PR1 and S1PR3 in mediating these effects, it was not clear which receptor was precisely responsible. Similar observations were reported in breast cancer cells, but here, S1P-induced migration was mediated through G αq [33] . Although knockdown of G αq or S1PR3 inhibited AKT phosphorylation, the authors did not provide a direct role for S1PR3 in mediating the migration of breast cancer cells through AKT. Therefore, we are the first to demonstrate that S1PR3 stimulates cell migration via the activation of AKT.
The pro-migratory feature of S1PR3 was also reported to be mediated through the accumulation of phosphorylated ERK1/2 into membrane ruffles/lamellipodia and the nucleus of the breast cancer cell line MCF-7 [34] . In the present study, S1P induced the phosphorylation of ERK in NPC cells; however, knockdown of SPHK1 did not affect the levels of phosphorylated ERK (data not shown). Nonetheless, we cannot rule out the possibility that S1PR3 can also mediate the S1P-induced migration of NPC cells through mechanisms other than AKT activation. S1P/S1PR3 signalling has been shown to promote cancer cell migration/invasion by up-regulating the expression of epidermal growth factor receptor (EGFR), hypoxia-induced factor-1 (HIF-1) or C-reactive protein (CRP) [35] [36] [37] . The identification of effector(s) downstream of S1P/S1PR3/AKT signalling that stimulate the migration of NPC cells warrants further investigation. Further, we noted that knockdown of S1PR3 did not completely suppress the S1P-induced migration in SUNE1 cells. There are two possible reasons to explain these observations: one is the incomplete knockdown of S1PR3, and the second is that another S1P receptor(s) might also be involved. Given that the up-regulation of S1PR5 was demonstrated in one of the microarray studies (supplementary material, Table S2), the involvement of this receptor in S1P-induced migration of NPC cells cannot be ruled out. Although the role of S1PR5 in tumourigenesis is still uncertain, it remains a possibility that by coupling to G i , S1PR5 can trigger Rac, which leads to an increase in NPC cell migration.
It has been shown that SPHK1 and S1PR3 function in an amplification loop to promote the migration of breast cancer cells [34] . However, we did not observe any consistent changes in S1PR3 expression following either knockdown of SPHK1 or EBV infection of NPC cells (data not shown). Since C15 is the only NPC xenograft that expresses LMP1, the high-level expression of S1PR3 in C15 prompted us to investigate whether LMP1 could modulate S1PR3 expression. However, of the 19 tumours in this series that were also stained for LMP1, we did not observe a correlation between S1PR3 and LMP1 expression (data not shown). Therefore, the mechanisms that regulate S1PR3 expression in NPCs remain to be determined and our data suggest that the expression of SPHK1 and S1PR3 in NPC cells is regulated by different mechanisms. Irrespective of these differences, high levels of SPHK1 in NPCs have been correlated with poor patient prognosis [10] and high-level expression of S1PR3 in the present study is associated with a worse overall survival in NPC patients (p < 0.05; supplementary material, Figure S6 ), data that are in line with those of Watson et al, who reported an association between high S1PR3 expression and shorter disease-specific survival in breast cancer patients [38] .
In summary, we report for the first time that S1P is likely produced by NPC cells through the up-regulation of SPHK1 following EBV infection, and that S1P contributes to a migratory phenotype of NPC cells by activating AKT through S1PR3. Our data highlight the potential of targeting of the SPHK1/S1P/S1PR3 axis in NPC patients. 
